Keymed Biosciences Co.Ltd
Quick facts
Phase 3 pipeline
- CM310 · Oncology
CM310 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. - CM326 · Oncology
CM326 is a monoclonal antibody that targets and inhibits OX40, a co-stimulatory immune checkpoint receptor, to enhance T-cell activation and anti-tumor immunity. - Stapokibatrt · Other
Phase 2 pipeline
- CM338 Injection · Oncology
CM338 Injection is a monoclonal antibody targeting the PD-1 receptor. - CM512
CM512 is an investigational therapeutic targeting a specific molecular pathway in early clinical development by Keymed Biosciences.
Phase 1 pipeline
- CM313-Dose escalation
- CM336_group 3a
- CM336_group 3b
- CM336_group 4a
- CM336_group 4b
- CM336_group 5
- CM336_group 6a
- CM336_group 6b
- CM336_group 7
- CM336_group 8a
- CM336_group 8b
- CM336_group 9
- CM336_RP2D
- CM350 group1
- CM383
- CM518D1
- CM559
- CMG901
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: